Tirzepatide adds hepatoprotection to its armoury

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

(2022) Alessandro Mantovani et al.   Lancet Gastroenterology & Hepatology

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

(2021) Alessandro Mantovani et al.   Metabolites

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

(2021) Giovanni Targher et al.   Lancet Gastroenterology & Hepatology

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(2021) Bernhard Ludvik et al.   LANCET

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

(2020) Jonathan G. Stine et al.   Clinical Gastroenterology and Hepatology

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

(2017) Michael S. Middleton et al.   GASTROENTEROLOGY